Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Cancer Press Releases at Novartis Oncology

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

Press Releases

10-Dec-2009

Further analysis of BIG 1-98 data supports survival advantage for Novartis drug Femara® over tamoxifen in breast cancer patients

Select a year: 2010 | 2009 | 2008 | 2007 | 2006

11-Dec-2006

Pivotal submission data shows Tasigna® achieved impressive response rates in chronic myeloid leukemia patients no longer helped by Glivec®

 

 

06-Dec-2006

Glivec® demonstrates highest five-year overall survival rate in history of treatment for patients with chronic myeloid leukemia

 

 

02-Oct-2006

New four-year results of major trial confirm Femara® significantly cuts risk of breast cancer recurrence and spread after surgery

 

 

19-Sep-2006

Glivec® receives additional EU approvals for use in treating a rapidly progressive form of leukemia and a hard-to-treat solid cancer tumor

 

 

30-Aug-2006

Exjade®, a breakthrough for patients with transfusional iron overload, gains European Union approval

 

 

14-Jun-2006

Patients with treatment-resistant leukemia achieve high responses to Tasigna® (nilotinib) in first published clinical trial results

 

 

04-Jun-2006

Novartis launches global program expanding access to investigational compound nilotinib (AMN107) for patients with hard-to-treat leukemia

 

 

03-Jun-2006

Glivec® sets new treatment standard in chronic myeloid leukemia with high overall survival, increasing response and decreasing progression

 

 

24-Apr-2006

Novartis delivers strong start to 2006 in first quarter with excellent sales and earnings growth performance

 

 

10-Apr-2006

Novartis completes submissions in US and Europe for Glivec® as treatment for four rare types of cancer

 

‹   1-10   11-20   ›  

12 Total results

 

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

 

SEARCH OUR WEBSITES

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.